ライフサイエンスコーパス: cystatin C

1 markers of filtration (serum creatinine and cystatin C).

2 ment (R(2) = 0.989 for CRP; R(2) = 0.939 for cystatin C).

3 l, 0.8-4.1] per standard deviation change in cystatin C).

4 cells (DC) are the predominant producers of cystatin C.

5 established renal function indices eGFR and cystatin C.

6 rmined by longitudinal measurements of serum cystatin C.

7 tory activity or amyloidogenic properties of cystatin C.

8 ar filtration rate (GFR), estimated GFR, and cystatin C.

9 a traditional sandwich immunoassay for serum cystatin C.

10 han when cells were incubated with wild-type cystatin C.

11 rovement in reclassification with the use of cystatin C.

12 s illustrated by incubating cells with W106F-cystatin C.

13 We estimated GFR using cystatin C.

14 inine, 24% did not have CKD by either ACR or cystatin C.

15 inine, 3863 (16%) had CKD detected by ACR or cystatin C.

16 terminal pro-B type natriuretic peptide, and cystatin C.

17 ylarginine, high-sensitivity troponin T, and cystatin C.

18 equation based on both plasma creatinine and cystatin C.

19 for legumain is 100-fold higher than that of cystatin C.

20 are never labelled with anti-TDP-43 or anti-cystatin C.

21 explaining 2.8% of the observed variation in cystatin C.

22 data for amyloids from either cystatin B or cystatin C.

23 rer prognosis within cohorts of high and low cystatin C.

24 proteinuria, and a 6-fold increase in serum cystatin-C.

25 ctive treatment's effect and EF on change in cystatin-C.

26 tin vs placebo; P = .033) and decreased mean cystatin C (-0.034 mg/L vs 0.010 mg/L; P = .008).

27 ive protein -0.0363 (95% CI 0.0601--0.0124), cystatin C -0.0391 (95% CI -0.0772--0.00107).

28 ct to limits of detection (CRP, 0.10 mug/mL; cystatin C, 0.003 mug/mL) and coefficients of variation

29 he extracellular cysteine protease inhibitor cystatin C, 12 variants of the protein were produced and

30 nd coefficients of variation (CRP, 2.4-7.0%; cystatin C, 3.0-8.9%).

31 rs911119 was associated with decreased serum cystatin C (6.13% per allele; 95% CI: 5.75 to 6.50; p =

32 l relative risk for CVD of 1.00 per doubling cystatin C (95% CI: 0.82 to 1.22; p = 0.994), which was

33 factors (relative risk: 1.82 per doubling of cystatin C; 95% confidence interval [CI]: 1.56 to 2.13;

34 alysis, we examined the relationship between cystatin C (a marker of renal function) and PASP and pot

35 al serum potassium levels and measurement of cystatin C, a non-creatinine measure of kidney function.

36 All cells internalized cystatin C added to culture media, leading to increased

37 , we developed estimating equations based on cystatin C alone and in combination with creatinine in d

38 The use of cystatin C alone or in combination with creatinine stren

39 lculated by the measurement of creatinine or cystatin C alone or in combination with creatinine, with

40 .9-2.7) for participants with CKD defined by cystatin C alone, and 3.0 (95% CI, 2.4-3.7) for particip

41 etter than equations that used creatinine or cystatin C alone.

42 dict mortality as well as equations based on cystatin C alone.

43 e offspring, suggesting the presence of L68Q cystatin C amyloid affected sperm function.

44 Hereditary cystatin C amyloid angiopathy is an autosomal dominant d

45 L68Q protein deposits in human cystatin C amyloid angiopathy patients have also been fo

46 In hereditary cystatin C amyloid angiopathy, a cystatin C variant is d

47 d causes a fatal amyloid disease, hereditary cystatin C amyloid angiopathy.

48 howed increased levels and distinct forms of cystatin C amyloid that were not present in WT mice.

49 Cystatin C amyloids cause a hereditary form of cerebral

50 L68Q epididymal fluid that was depleted of cystatin C amyloids, however, did not impair the motilit

51 cohorts (n = 76,481) with 37,126 measures of cystatin C and added genetic data from 43 studies (n = 2

52 Higher cystatin C and beta trace protein associated with a high

53 m underlying the strong relationship between cystatin C and cardiovascular risk.

54 ult ICU survivors, we compared ICU discharge cystatin C and creatinine and their association with 1-y

55 During ICU admission, serum cystatin C and creatinine diverged, so that by ICU disch

56 s of estimating GFR, equations based on both cystatin C and creatinine do not predict mortality as we

57 ge in the C statistic was noted with FRSVs + cystatin C and FRSVs + creatinine compared with FRSVs al

58 d to determine the association between serum cystatin C and mortality.

59 espectively, of the indirect effects between cystatin C and PASP.

60 Rosuvastatin 10 mg daily reduces plasma cystatin C and slows kidney function decline in HIV-infe

61 highly ordered, domain-swapped assemblies of cystatin C and that the oligomers could not build larger

62 This, along with the rise of serum cystatin C and the reduced inulin and creatinine clearan

63 Here we aimed to investigate if uptake of cystatin C and the related inhibitor cystatin E/M occur

64 we evaluate endogenous cathepsin inhibitors cystatins C and B.

65 y cardiac troponin T), renal (creatinine and cystatin-C), and hepatic (aspartate transaminase and ala

66 for those with CKD defined by creatinine and cystatin C, and 5.6 (95% CI, 3.9-8.2) for those with CKD

67 od gas, inflammatory cytokine concentration, cystatin C, and alanine aminotransferase.

68 er adjustment for GFR, levels of creatinine, cystatin C, and beta trace protein, each remained direct

69 immunosorption, using immobilized monomeric cystatin C, and elution from columns with immobilized cy

70 -stratified models with FRSVs alone, FRSVs + cystatin C, and FRSVs + creatinine.

71 Four markers (albumin, beta-2-microglobulin, cystatin C, and osteopontin) were undetectable in most A

72 many solutes, including carboxymethyllysine, cystatin C, and parathyroid hormone.

73 isease Epidemiology Collaboration creatinine-cystatin C, and urate and high-sensitivity C-reactive pr

74 with increased aortic pulsed wave velocity, cystatin C, and urinary albumin-to-creatinine ratio.

75 Conversely, lower creatinine relative to cystatin C appeared to confer adverse prognosis, confoun

76 herapeutics targeted at lowering circulating cystatin C are unlikely to be effective in preventing CV

77 implications for the diagnostic use of serum cystatin C as a marker of kidney function during inflamm

78 isual readout and applied it to an assay for cystatin C as a model target.

79 fication improvement with the measurement of cystatin C, as compared with creatinine, was 0.23 (95% c

80 FR to a higher value with the measurement of cystatin C, as compared with creatinine, was associated

81 igher than SCr (AUC-ROC=0.73) and similar to cystatin C (AUC-ROC=0.91).

82 mination of renal function by creatinine and cystatin C-based eGFR revealed decreasing eGFRs in the d

83 (2) of body-surface area was higher with the cystatin C-based eGFR than with the creatinine-based eGF

84 s were consistent for creatinine-based eGFR, cystatin C-based eGFR, and UACR.

85 tly associated with childhood kidney volume, cystatin C-based eGFR, or the risk of microalbuminuria.

86 inine-based equation only, 2% had CKD by the cystatin C-based equation only, and 4% had CKD by both e

87 he subset who also have CKD according to the cystatin C-based equation.

88 We defined a rapid decline in cystatin C-based estimated GFR as >3 ml/min per 1.73 m(2

89 Kidney function was measured by cystatin C-based estimated glomerular filtration rate (e

90 3.51) in models adjusted for age, sex, race, cystatin C-based estimated glomerular filtration rate, b

91 One of 3 CKD stages diagnosed by cystatin c-based formulas was incorrect, with both overe

92 We compared 51 creatinine-based and/or cystatin c-based formulas with a gold standard (iohexol

93 e-based formulas: approximately 0.70 and for cystatin c-based formulas: approximately 0.85).

94 012) was superior to previous creatinine- or cystatin C-based GFR equations.

95 , and previously reported creatinine- and/or cystatin C-based GFR-estimating equations.

96 We estimated cystatin C-based glomerular filtration rate (eGFR(cys))

97 lable creatinine at baseline (n=17 951), and cystatin C-based glomerular filtration rate was estimate

98 our knowledge, no previous studies have used cystatin C-based measures of the estimated glomerular fi

99 IS1: creatinine-based; BIS2: creatinine- and cystatin C-based) with other estimating equations and de

100 0% (creatinine-based) and approximately 50% (cystatin c-based), indicating that 90% of the estimation

101 We further assessed the impact of using cystatin-C-based eGFR in risk prediction equations for C

102 and international guidelines recommend that cystatin-C-based estimates of GFR be used to confirm or

103 Whilst there is good evidence for cystatin C being a marker of GFR and risk in people with

104 nt variable for kidney function (creatinine, cystatin C, beta2-microglobulin).

105 sC5b-9) and renal injury markers (clusterin, cystatin-C, beta2-microglobulin, and liver fatty acid bi

106 red childhood kidney volumes, creatinine and cystatin C blood levels, microalbuminuria, BP, and eGFR.

107 which was based on height, serum creatinine, cystatin C, blood urea nitrogen, and gender.

108 Statins may improve cystatin C by improving glomerular function or by decrea

109 Serum cystatin C, by itself or as a part of an estimated GFR,

110 m2, calculated using the combined creatinine-cystatin C CKD-Epidemiology Collaboration Equation.

111 omarkers (haemoglobin, cTn-hs, and GDF-15 or cystatin C/CKD-EPI) was internally and externally valida

112 ss than 60 mL/min/1.73 m when estimated from cystatin C compared with glomerular filtration rate esti

113 baseline and 0- to 24-week changes in plasma cystatin C concentration with measures of vascular disea

114 CIAKI (ie, an increase >10% of serum cystatin C concentration within 24 hours after CM exposu

115 Cystatin C concentrations remained normal in both groups

116 Cystatin C concentrations were associated with CVD risk

117 ation rate (eGFR) using serum creatinine and cystatin C concentrations, and microalbuminuria using ur

118 In contrast to creatinine, cystatin C consistently associated with long-term mortal

119 Within the statin group, changes in cystatin C correlated with changes in endothelial activa

120 ence, the authors studied the association of cystatin C, creatinine-based estimated glomerular filtra

121 gh-sensitivity cardiac troponin T (hs-cTnT), Cystatin-C (Cys-C), high-sensitivity C-reactive protein

122 We investigated whether cystatin C (CysC) and neutrophil gelatinase-associated l

123 tion rate (GFR) equations incorporating both cystatin C (CysC) and serum creatinine (Creat) in living

124 Cystatin C (CysC) is a better glomerular filtration rate

125 Cystatin C (CysC) is a versatile and ubiquitously-expres

126 In vitro studies have shown that cystatin C (CysC) is neuroprotective.

127 t renal function measures are imperfect, and cystatin C (CysC) is promoted as a better marker of glom

128 ating fragments but is potently inhibited by cystatin C (CysC).

129 tB is inhibited by its endogenous inhibitor, cystatin C (CysC).

130 ins and their principal endogenous inhibitor cystatin C (CystC) may favor proteolysis in the pathogen

131 the legumain binding region (N39K- and N39A-cystatin C) decreased the internalization and (R24A,R25A

132 1 promotes fibrosis by driving the effective cystatin C-dependent inhibition of extracellular matrix-

133 ) in young and middle-aged adults who have a cystatin C-derived estimated glomerular filtration rate

134 D) in children, such as creatinine level and cystatin C-derived estimated glomerular filtration rate

135 measurement method of renal function such as cystatin-C-derived or directly measured GFR.

136 e intracellular concentration of ROS inhibit cystatin C dimerization.

137 These could be used to selectively remove cystatin C dimers from biological fluids containing both

138 s, and of the potential legumain inhibitors, cystatin C, E/M, and F, cystatin C was the one mainly pr

139 ed GFR estimated from creatinine (eGFR(Cr)), cystatin C (eGFR(Cys)), or both (eGFR(Cr+Cys)) with ioth

140 reatinine (eGFR_Cr), and eGFR estimated from cystatin C (eGFR_cysC).

141 e Epidemiology Collaboration eGFR creatinine-cystatin C (eGFRcreat-cys) equation.

142 eGFR by cystatin C (eGFRcys) and albumin-to-creatinine ratio wer

143 imated by serum creatinine (eGFRcrea), serum cystatin c (eGFRcys) and CKD (eGFRcrea < 60 ml/min/1.73

144 We estimated GFR using both cystatin C (eGFRcys) and creatinine (eGFRcreat).

145 GFR should be calculated and reported using cystatin C (eGFRcys) and serum creatinine (eGFRcr-cys) o

146 d GFR estimated from creatinine (eGFRcreat), cystatin C (eGFRcys), and both (eGFRcreat-cys) at baseli

147 estimated by serum creatinine (eGFRcrea) and cystatin C (eGFRcys), and CKD (eGFRcrea < 60 ml/min/1.73

148 diagnostic performance of CKD-EPI creatinine-cystatin C equation (2012) in patients with cirrhosis wa

149 Performance of the new CKD-EPI creatinine-cystatin C equation (2012) was superior to previous crea

150 73 m(2) with the creatinine equation and the cystatin C equation (P=0.07 and P=0.05), respectively.

151 r the BIS2 equation (11.6%), followed by the cystatin C equation 2 (15.1%) proposed by the Chronic Ki

152 Accuracy of CKD-EPI creatinine-cystatin C equation as quantified by root mean squared e

153 ubjects, GFR estimated by CKD-EPI creatinine-cystatin C equation differed from the mGFR by more than

154 te the performance of the CKD-EPI creatinine-cystatin C equation in subjects with cirrhosis, we compa

155 The combined creatinine-cystatin C equation performed better than equations base

156 In the validation data set, the creatinine-cystatin C equation performed better than equations that

157 and "accuracy" of the new CKD-EPI creatinine-cystatin C equation to that of 24-hour urinary creatinin

158 Cystatin C, estimated GFR, and albuminuria were not asso

159 Cystatin C forms non-inhibitory dimers and aggregates by

160 ongestion end point) and the change in serum cystatin C from enrollment to 72 hours (renal function e

161 Furthermore, immunodepletion of cystatin C from the conditioned medium completely remove

162 Vimentin, cystatin C, galectin-1, IGFBP-7, and secreted protein, a

163 y C-reactive protein greater than 3.0 mg/dL, cystatin C >/=1.11 mg/dL, estimated glomerular filtratio

164 tive protein, urinary albumin excretion, and cystatin-C had similar risk for new-onset HF between bot

165 Serum cystatin C has an important role in enhancing accuracy o

166 from serum concentrations of creatinine and cystatin C has been refined using cross-sectional data f

167 Equations incorporating cystatin C improve the estimation of GFR, but whether th

168 ne the extent to which the addition of serum cystatin C improves glomerular filtration rate (GFR) est

169 vation and inflammation were associated with cystatin C in a multivariable model independent of creat

170 l variable to investigate the causal role of cystatin C in CVD, including coronary heart disease, isc

171 s 6.4% (P < .001) after adding estimated GFR cystatin C in fully adjusted models with estimated GFR c

172 (from 0.64 (49 nM) to 0.96 mg/L (74 nM)) of cystatin C in serum.

173 on analyses did not support a causal role of cystatin C in the etiology of CVD.

174 cell types synthesize monomeric and dimeric cystatin C in vivo, but only secrete monomer.

175 ulative urine volume and the change in serum cystatin-C in 72 hours.

176 An equation using both creatinine and cystatin C (in addition to age, race, and gender) result

177 t and confirmed an increased uptake of W106F-cystatin C, in PC3 cells.

178 of GFR-estimating equations with and without cystatin C, including the modification of diet in renal

179 ile serum creatinine fell at 12 hours, serum cystatin C increased, suggestive of decreased creatinine

180 , galectin-3, midregional proadrenomedullin, cystatin-C, interleukin-6, procalcitonin, and others.

181 prostate cancer cells corroborated that the cystatin C internalization is generally relevant and con

182 Although cystatin C is a stronger predictor of clinical outcomes

183 Cystatin C is an alternative filtration marker for estim

184 iological studies show that high circulating cystatin C is associated with risk of cardiovascular dis

185 ndelian randomization to investigate whether cystatin C is causally related to CVD in the general pop

186 The cysteine protease inhibitor cystatin C is internalized by some cancer cells, which a

187 Low extracellular cystatin C is linked to pathologic protease activity in

188 Our assay for serum cystatin C is more sensitive and specific than serum cre

189 If cystatin C is not available, the BIS1 equation is an acc

190 The cysteine protease inhibitor cystatin C is thought to be secreted by most cells and e

191 he extracellular concentration of inhibitory cystatin C is thus partly dependent on the abundance of

192 h CKD than creatinine, the clinical role for cystatin C is unclear.

193 Relationships between cystatin C, kidney function, and cardiovascular risk in

194 dominant disorder in which a variant form of cystatin C (L68Q) readily forms amyloid deposits in cere

195 714 to 1171 mL; P = .59) or on the change in cystatin C level (dopamine, 0.12 mg/L; 95% CI, 0.06-0.18

196 618 to 1176 mL; P = .49) or on the change in cystatin C level (nesiritide, 0.07 mg/L; 95% CI, 0.01-0.

197 ely associated with childhood creatinine and cystatin C levels (all P values <0.05), but did not asso

198 hsCRP, IL-6, D-dimer, and cystatin C levels are elevated in persons with HIV infec

199 re media, leading to increased intracellular cystatin C levels by 120-200%.

200 ells are major contributors to extracellular cystatin C levels in healthy mice.

201 ntly higher serum phosphate, creatinine, and cystatin C levels than those without CRD.

202 filtration rate (GFR) was estimated based on cystatin C levels using the relevant equation.

203 stimated glomerular filtration rate based on cystatin C levels using the relevant equation.

204 tudy participants, hsCRP, IL-6, D-dimer, and cystatin C levels were 50%, 152%, 94%, and 27% higher, r

205 ated on the basis of creatinine (eGFRcr) and cystatin C levels were assessed in </=1735 participants

206 Cystatin C levels were positively and plasma high-densit

207 After adjustment for both creatinine and cystatin C levels, higher discharge creatinine was then

208 easured GFR from standardized creatinine and cystatin C levels, sex, and age in the learning sample;

209 ut cirrhosis using both serum creatinine and cystatin C levels.

210 -treated groups had a 35% reduction in serum cystatin-C levels and reduced crescent numbers compared

211 allel with Elmo1, as do the plasma levels of cystatin C, lipid peroxides, and TGFbeta1, and erythrocy

212 munodeficiency virus (HIV) infection, plasma cystatin C may be influenced by factors other than glome

213 Cystatin C may have a role in identifying persons with C

214 imilarly, both in patients with high and low cystatin C (median cut-off), higher plasma NGAL levels w

215 )=39.1[height (m)/Scr (mg/dl)](0.516) x [1.8/cystatin C (mg/L)](0.294)[30/BUN (mg/dl)](0.169)[1.099](

216 ed GFR, the formula with both creatinine and cystatin C, namely, CKD-epidemiology cr-cys, outperforme

217 phosphatase, gamma-glutamyl transpeptidase, cystatin C, neutrophil gelatinase-associated lipocalin,

218 Except for a modest effect of cystatin-C, no biomarker was associated with increased r

219 n rate (GFR) determined by creatinine and by cystatin C of either <60 or >/=60 mL/min/1.73 m(2) and A

220 C, and elution from columns with immobilized cystatin C oligomers, oligomer-specific antibodies were

221 We measured cystatin C on 6942 adult participants in the Third Natio

222 <60 ml/min per 1.73 m(2)): creatinine only, cystatin C only, both, or neither.

223 .002), and GFR-estimating equations based on cystatin C only.

224 only; 3.23 (95% CI 1.84 to 5.67) for CKD by cystatin C only; and 1.93 (95% CI 1.27 to 2.92) for CKD

225 In models including either cystatin C or beta trace protein, the association of GFR

226 all and not significant with the addition of cystatin C or creatinine to FRSVs.

227 tudied the incremental value of adding serum cystatin C or creatinine to the Framingham risk score va

228 ted using equations that incorporated either cystatin C or creatinine, and CKD was defined by estimat

229 In contrast, cystatin C or high-sensitivity C-reactive protein did no

230 In conclusion, the addition of cystatin C or serum creatinine to FRSVs does not improve

231 Serum levels of creatinine, cystatin C, or beta trace protein allow estimation of GF

232 lternative biomarkers (haematocrit, cTnI-hs, cystatin C, or creatinine clearance) also outperformed t

233 not increase albuminuria, proteinuria, serum cystatin C, or serum creatinine levels in TxNIP(-/-) mic

234 plasma biomarkers of renal injury including Cystatin C, Osteopontin, Tissue Inhibitor of Metalloprot

235 = .026, area under ROC curve [AUC] = 0.818), cystatin C (P = .033, AUC = 0.805), and creatinine (P =

236 le risk prediction model, eGFR (P=0.616) and cystatin C (P=0.937) were no longer associated with mort

237 In addition, cystatin C participated in the control of extracellular

238 bining a functional damage biomarker (plasma cystatin C [pCysC]) with a tubular damage biomarker (uri

239 8.30-21.2); Pnoninferiority = 0.0011], serum cystatin C (Pnoninferiority < 0.0001), serum creatinine

240 ons, little is known about the regulation of cystatin C production, dimerization, and secretion.

241 of cystatin C under the control of the mouse cystatin C promoter were unable to generate offspring, s

242 n decline of eGFR (Ptrend<0.001) and rise of cystatin C (Ptrend=0.01) and creatinine (Ptrend<0.001) l

243 mo Diet and Cancer study (MDC) into baseline cystatin C quintiles (n=4757).

244 atinine measure but detected by both ACR and cystatin C (rate per 1000 person-years, 6.4; 95% CI, 3.6

245 ation coefficient, serum creatinine-to-serum cystatin C ratio was found to be the best performer in t

246 ient increase in serum creatinine, but serum cystatin C remained stable.

247 renal function, C-reactive protein (CRP) and cystatin C, respectively.

248 ith increases in endothelin-1 and creatinine/cystatin C, respectively.

249 ly by iothalamate and creatinine (eGFRcr) or cystatin C, respectively.

250 he control group; Chromogranin-A[rs9658644], Cystatin-C[rs2424577] and Vitamin K-Dependent Protein S[

251 The role of serum cystatin C (Scyc), neutrophil gelatinase-associated lipo

252 t this effect is mediated via an increase in cystatin C secretion.

253 beta trace protein and cystatin C seem to provide more consistent prognostic in

254 ss or diet), or interference with the assay, cystatin C should be measured and estimated GFR should b

255 Two variants, W106F- and K75A-cystatin C, showed that the internalization can be posit

256 ation, we use redox experiments of monomeric cystatin C, stabilized against domain swapping by an int

257 atients had lower levels of cardiotrophin-1, cystatin C, syndecan-4, and N terminal-probrain natriure

258 ciated with mortality when assessed by serum cystatin C than by creatinine.

259 inar-specific markers-namely, alpha-amylase, cystatin C, TMEM16A, and NKCC1.

260 , these results suggest that the addition of cystatin C to creatinine to estimate GFR may improve ide

261 Adding the measurement of cystatin C to that of serum creatinine to determine the

262 Adding cystatin C to the combination of creatinine and ACR meas

263 neutrophil gelatinase-associated lipocalin, cystatin C, trefoil factor 3, tissue inhibitor of metall

264 L68Q) that express the human L68Q variant of cystatin C under the control of the mouse cystatin C pro

265 down-regulated in cell homogenates following cystatin C uptake.

266 Further adjustment for serum cystatin C, urinary albumin/creatinine ratio, and arteri

267 hereditary cystatin C amyloid angiopathy, a cystatin C variant is deposited in arterial walls and ca

268 Cystatin C warrants further investigation as a more mean

269 ne eGFR was 54+/-20 mL/min per 1.73 m2, mean cystatin C was 11.2 (7.7-16.2) mg/L, and median plasma N

270 Concurrent serum cystatin C was assayed in banked serum samples.

271 Baseline cystatin C was associated with higher carotid intima-med

272 Log cystatin C was directly associated with PASP (adjusted b

273 In contrast, the cysteine protease inhibitor cystatin C was expressed only in tubules.

274 ysis adjusted for age, sex, and comorbidity, cystatin C was near-linearly associated with increased m

275 A causal effect of cystatin C was not detected for any individual component

276 Although mRNA expression of cystatin C was stable, its secretion, which was inhibite

277 Lower estimated GFR based on cystatin C was strongly associated with higher risk for

278 legumain inhibitors, cystatin C, E/M, and F, cystatin C was the one mainly produced.

279 A secreted factor, identified as cystatin C, was found to be responsible for this effect.

280 ge glomerular filtration rate estimated from cystatin C well matched follow-up chronic kidney disease

281 mated glomerular filtration rate (eGFR), and cystatin C were assessed in 562 patients with heart fail

282 ardized measurements of serum creatinine and cystatin C were available.

283 in (hsCRP), interleukin (IL)-6, D-dimer, and cystatin C were compared in 494 HIV-infected individuals

284 ng; urinary albumin-to-creatinine ratio; and cystatin C were evaluated at study baseline.

285 Levels of cystatin C were higher in the Tg2576 conditioned medium

286 Several variants of cystatin C were identified and quantified, while none we

287 kidney disease and when both creatinine and cystatin C were used to calculate the eGFR.

288 L9G,V10G)-, (R8G,L9G,V10G,W106G)-, and W106G-cystatin C) were internalized to a very low extent compa

289 binding protein, urinary interleukin-18, and cystatin C) were measured in 1,635 unselected emergency

290 n factor 15), GAL-3 (galectin-3), and Cys-C (cystatin-C) were assessed before TAVR and in 100 sex-mat

291 eded in a number of assays, such as that for cystatin C, where a 1.5-fold increase in concentration m

292 ration equation, the eGFR was estimated from cystatin C with all available samples per participant ex

293 extent comparable with the W106F variant of cystatin C with optimal uptake properties and resulting

294 Reductions in cystatin C with statin therapy correlate with reductions

295 ed vesicular co-localization of internalized cystatin C with the lysosomal marker proteins cathepsin

296 eaker associations than equations using only cystatin C (with or without age, race, and gender).

297 id not provide evidence for a causal role of cystatin C, with a causal relative risk for CVD of 1.00

298 terminal pro-B-type natriuretic peptide, and cystatin C, with longer QRS interval, with lower heart r

299 utrophil gelatinase-associated lipocalin and cystatin C, with poorer survival.

300 ecreased the internalization and (R24A,R25A)-cystatin C, with substitutions of charged residues not i